Table 4. Clinical features of participants with and without coenzyme Q10 exposure.

CoQ10 exposure	SCA1		SCA2		SCA3		SCA6
	Yes	No	Yes	No	Yes	No	Yes	No
Sample size, n	14	39	9	60	31	98	20	48
Mean age, years	50.0 ± 9.4	50.4 ± 14.2	51.7 ± 11.6	50.8 ± 13.8	52.3 ± 11.2	51.1 ± 12.6	65.9 ± 9.7	65.3 ± 11.3
Male, %	28.6	51.3	33.3	43.3	58.1	44.9	40	45.8
White race, %	100	87.2	77.8	73.3	71	49	95	89.6
Age at onset, years	40.5 ± 12.1	40.1 ± 11.7	41.3 ± 13.1	35.6 ± 11.7	41.7 ± 10.9	38 ± 12.1	52.9 ± 10.6	52.1 ± 10.5
Disease duration, years	8.1 ± 9.0	9.1 ± 6.2	9.1 ± 4.7	14.3 ± 8.6	9.3 ± 6.5	12.2 ± 8.1	11.6 ± 11.5	11.7 ± 10.1
CAG repeats	45.9 ± 2.8	46.2 ± 4.9	38.8 ± 2.2	39.7 ± 3.8	71.2 ± 3.5	70.6 ± 4.2	22.4 ± 0.7	22.4 ± 1.0
Baseline SARA	9.2 ± 5.8	16.2 ± 8.2	13.7 ± 5.7	17.6 ± 7.5	12.5 ± 8.3	16.0 ± 9.0	13.7 ± 8.5	14.2 ± 7.0
Concomitant drugs, n	5.4 ± 4.6	3.9 ± 3.2	4.1 ± 2.7	4.3 ± 3.6	6.1 ± 3.5	5.2 ± 4.2	6.8 ± 4.0	4.9 ± 4.4

Mean ± standard deviation is reported.